To improve the lives of patients suffering from lung disease, Pulmonx remains focused on developing life-changing, cost-effective technologies.
AeriSeal® System – Coming Soon
The AeriSeal treatment uses a polymeric foam to block diseased regions in the lung to achieve volume reduction and improve breathing function. The treatment is designed for patients with emphysema and is independent of collateral ventilation. AeriSeal received CE Mark approval at the end of 2015. Pulmonx is continuing to develop the post-market surveillance protocols and expects to be re-introducing the technology in 2017.